

VIRGINIA Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	8,466,900	8,917,400	9,364,300	9,825,000
Prediabetes	2,311,100	2,514,400	2,719,400	2,857,000
Diagnosed diabetes	665,900	830,800	980,800	1,111,100
Undiagnosed diabetes	238,700	282,800	316,800	340,000
Total with diabetes (diagnosed and undiagnosed)	904,600	1,113,500	1,297,600	1,451,100
Complications:				
Visual impairment	109,200	132,300	151,500	166,700
Renal failure	1,590	1,910	2,180	2,380
Leg amputations	1,380	1,580	1,720	1,790
Annual deaths attributable to diabetes	7,170	8,540	9,580	10,270
Total annual cost (2015 dollars)	\$9.5 B	\$11.7 B	\$13.6 B	\$15.2 B
Annual medical costs	\$7.1 B	\$8.6 B	\$10.0 B	\$11.1 B
Annual nonmedical costs	\$2.4 B	\$3.1 B	\$3.6 B	\$4.1 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	1,193,500	1,404,600	1,634,000	1,844,000
Prediabetes	608,700	716,300	833,300	940,400
Diagnosed diabetes	225,600	265,500	308,800	348,500
Undiagnosed diabetes	83,500	98,300	114,400	129,100
Total with diabetes (diagnosed and undiagnosed)	309,100	363,800	423,200	477,600
Complications:				
Visual impairment	42,200	48,400	54,800	60,300
Renal failure	700	790	890	970
Leg amputations	520	570	610	640
Annual deaths attributable to diabetes	4,950	5,720	6,220	6,470
Total annual cost (2015 dollars)	\$3.9 B	\$4.6 B	\$5.4 B	\$6.1 B
Annual medical costs	\$3.7 B	\$4.4 B	\$5.1 B	\$5.7 B
Annual nonmedical costs	\$0.2 B	\$0.2 B	\$0.3 B	\$0.4 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.